Last reviewed · How we verify

ACEI omission — Competitive Intelligence Brief

ACEI omission (ACEI omission) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

marketed Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ACEI omission (ACEI omission) — University of Nebraska. ACEI omission refers to the clinical practice of withholding or not prescribing ACE inhibitors, typically studied as a comparative intervention rather than a drug itself.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ACEI omission TARGET ACEI omission University of Nebraska marketed

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACEI omission — Competitive Intelligence Brief. https://druglandscape.com/ci/acei-omission. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: